juvenal ([info]juvenal) rakstīja,
@ 2024-06-06 00:22:00

Previous Entry  Add to memories!  Tell a Friend!  Next Entry
Nosūtīšu digitālajā visumā cerīgu ziņu... Jau rakstīju par locamidazole, kuru pēta kā "exercise drug": zālītes, lai iegūtu (visus) fitnesa un sporta labumus bez sportošanas.

Izrādās, ka ir vesela šāda zālīšu kategorija "exercise mimetics", kas tiek pētīta un kuru aktuālie pārskata raksti varētu būt:
https://www.sciencedirect.com/science/article/pii/S1728869X23000643
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891316/

Tajos ir arī izstrādē esošo zālīšu katalogi. Cik saprotu, tad īsti gatavas vēl nav nevienas. Un viena raksta sākumā jau arī saka, ka zālītes kļūstot aizvien grūtāk atklāt. Nu nezinu, neticu, ka grūtības nevar pārvarēt. Tieši otrādi - tur ir vieta atklājumiem, saprast, kas tad traucē.

Šajā gadījumā pētnieku viena no metodēm ir novērot biokīmiju muskulāros džekos un no tās mācīties, atklāt, kurus proteīnu ceļus mimicēt vai arī downstream/upstrem proteīnu ceļus.

Ir cilvēki, kuriem tās patiešām vajadzīgs šeit un tagad. Un tad ir bēdīgi.

Man pašam vajadzētu priecāties, ka esmu vesels, varu skriet, svarus celt, ar velo braukt. Bet tik ellīgi mokoši tas ir. Jādara, jādara. Bet pasaule liekas gaišāka, ja zini, ka cilvēki strādā, lai moku būtu mazāk.


(Lasīt komentārus) - (Ierakstīt jaunu komentāru)


[info]juvenal
2024-06-06 00:35 (saite)
Iekopēju GTP4o ģenerēto sarakstiņu ar tekošajām firmām un zālītēm, kas to pēta:

1. Acceleron Pharma
Drug: ACE-083
Mechanism: Myostatin inhibitor
Status: Acceleron has been investigating myostatin inhibitors for muscle growth in conditions like neuromuscular diseases.
2. Axcella Health
Drug: AXA1125 and AXA1957
Mechanism: Multifactorial metabolic modulators designed to improve muscle health and metabolic function.
Status: These drugs are in clinical development for metabolic diseases, including muscle atrophy.
3. Bayer
Drug: BAY 85-3934 (Molidustat)
Mechanism: PHD inhibitor that can potentially improve oxygen delivery and muscle function.
Status: Under investigation for anemia related to chronic kidney disease but has implications for muscle health.
4. CohBar
Drug: CB4211
Mechanism: Mitochondrial-derived peptide designed to improve insulin sensitivity and metabolic function.
Status: In early-stage clinical trials for metabolic diseases, with potential benefits for muscle health.
5. Novartis
Drug: Bimagrumab
Mechanism: Anti-myostatin monoclonal antibody.
Status: Initially developed for muscle-wasting diseases; now being explored for obesity and metabolic disorders.
6. Pfizer
Drug: PF-06252616 (Domagrozumab)
Mechanism: Myostatin inhibitor.
Status: Under development for Duchenne muscular dystrophy but has broader implications for muscle growth.
7. Amgen
Drug: AMG 745 (Trepidermin)
Mechanism: Myostatin pathway inhibitor.
Status: Amgen has been exploring various approaches to modulate muscle growth, including myostatin inhibition.
8. Mitobridge (Astellas)
Drug: MA-0211 (also known as ASP0367)
Mechanism: PPAR delta agonist.
Status: Focused on improving mitochondrial function and treating muscle diseases, including sarcopenia.
9. Regeneron Pharmaceuticals
Drug: REGN2477 (Garetosmab)
Mechanism: Myostatin inhibitor.
Status: Investigated for fibrodysplasia ossificans progressiva, a condition involving abnormal muscle growth.
10. Sarcopenia Therapeutics
Drug: Various compounds
Mechanism: Focused on developing therapies specifically targeting age-related muscle loss.
Status: Early-stage development and research.
11. Ligand Pharmaceuticals
Drug: VK5211 (LGD-4033)
Mechanism: Selective androgen receptor modulator (SARM)
Status: In clinical trials for muscle wasting and hip fracture recovery.

(Atbildēt uz šo)


(Lasīt komentārus) -

Neesi iežurnalējies. Iežurnalēties?